الفهرس | Only 14 pages are availabe for public view |
Abstract In conclusion, considering the value and safety of LB, and the current limitations of noninvasive tests, LB will continue to remain, in the nearby future, as the cornerstone and the gold standard test in the assessment of liver fibrosis and histology. Accordingly, treatment decision in less developed countries should be tailored to attain the highest cost effective disease outcome. While great efforts and advances have been made to improve noninvasive markers, nevertheless, major steps remain ahead before these tests can replace LB in both the information obtained and the accuracy in diagnosis. The relapse of patients could be predicted pretreatment by good patient selection, as well as patient sustained virological response |